Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Bullboard Posts
Comment by Annayyaon Sep 22, 2020 9:36pm
153 Views
Post# 31601910

RE:RE:RE:RE:RE:fall arrives, back to work

RE:RE:RE:RE:RE:fall arrives, back to work
I thought Anthony's expertise was to get a large number of investors to PMN and to work through the process of getting PMN listed on NASDAQ. Its been three and a half years and we are not on NASDAQ yet, and so maybe the board thought he doesn't have the time to focus enough on PMN so it's time for him to move on. He is a pretty busy man as you said. See the news from March 2017 below where the term NASDAQ was mentioned twice as his achievement. I was holding shares back then in PMN and my understanding was that he was the guy to take us to NASDAQ. 
 
"Anthony led the up-listing of Cynapsus from the TSX Venture exchange to the TSX and then the NASDAQ, attracting bulge bracket investment banks and some of the largest institutional life science investors in the USA." 
 

Alex1726 wrote:
For a biotech entrepreneur being in a team that will bring a potentially best in class therapy for AD is like a gold minor that thinks will discover a gold mine that has never been discovered before. YOU DO NOT LEAVE


Bullboard Posts